Journal of Inflammation Research (Feb 2021)
Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19
Abstract
Xiao-Yu Zhang,1,* Tao Li,2,* Haibing Wu,3 Yun Ling,4 Zhi-Ping Qian,5 Liang Chen1 1Department of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China; 2Department of Tuberculosis Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China; 3Department of Neurosurgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China; 4Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China; 5Department of Severe Hepatopathy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China*These authors contributed equally to this workCorrespondence: Liang Chen; Xiao-Yu ZhangDepartment of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of ChinaTel +8618930810000; +8613052251333Email [email protected]; [email protected]: This study is to evaluate the effect of proton-pump inhibitors on the course of COVID-19.Methods: Clinical data of moderate COVID-19 patients admitted to the Shanghai Public Health Clinical Center for treatment from January 20, 2020, to March 16, 2020, were collected. A retrospective study was conducted and the patients were divided into two groups according to whether they used proton-pump inhibitors or not. The differences in SARS-CoV-2 clearance and hospital stay between the two groups were compared by Cox proportional hazards (PH) regression models and the propensity score matching method.Results: A total of 154 patients with moderate COVID-19 were included in this study, including 80 males (51.9%), 35 patients (22.7%) in the proton-pump inhibitor group, and 119 patients (77.3%) in the control group. In the proton-pump inhibitor group and the control group, the duration of the SARS-CoV-2 clearance was 7 days (95% CI, 6– 9) and 7 days (95% CI, 6– 11), and the duration of the hospital stay was 21 days (95% CI, 16– 25) and 20 days (95% CI, 15– 26), respectively. There was no significant difference between the both groups in the cumulative incidence of the SARS-CoV-2 clearance and the discharge, and the same results were obtained after the propensity score matching, all P > 0.05. There was no significant association between the use of proton-pump inhibitors and the duration of SARS-CoV-2 clearance, according to univariate analysis (HR, 1.309; 95% CI, 0.893– 1.918) and multivariate analysis (HR, 1.575; 95% CI, 0.993– 2.499). There was no significant association between the use of proton-pump inhibitors and the duration of hospital stay for COVID-19, according to univariate analysis (HR, 1.044; 95% CI, 0.714– 1.528) and multivariate analysis (HR, 1.064; 95% CI, 0.651– 1.740).Conclusion: The use of proton-pump inhibitors has no effect on prolonging or shortening the course of adults hospitalized with COVID-19.Keywords: COVID-19, SARS-CoV-2, proton-pump inhibitors, SARS-CoV-2 clearance, hospital stay
